

# Chiara Cicarese

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3967769/chiara-cicarese-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

1,214  
citations

18  
h-index

32  
g-index

88  
ext. papers

1,505  
ext. citations

5.3  
avg, IF

4.12  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 77 | Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 45, 46-57  | 14.4 | 117       |
| 76 | The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e645-e653  | 3.3  | 68        |
| 75 | Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 767-76   | 14.4 | 55        |
| 74 | Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 68-73   | 14.4 | 52        |
| 73 | Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. <i>PLoS ONE</i> , <b>2014</b> , 9, e103918  | 3.7  | 52        |
| 72 | Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , <b>2016</b> , 11, 345-51  | 5    | 48        |
| 71 | Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 81-90  | 7    | 45        |
| 70 | The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 49, 37-44   | 14.4 | 42        |
| 69 | AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 43, 27-35  | 14.4 | 41        |
| 68 | Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , <b>2015</b> , 1, FSO15  | 2.7  | 39        |
| 67 | Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. <i>Oncology Reviews</i> , <b>2016</b> , 10, 293  | 4.3  | 38        |
| 66 | Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 809-24   | 5.9  | 34        |
| 65 | De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 67-74  | 14.4 | 26        |
| 64 | Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 60, 152-157   | 14.4 | 25        |
| 63 | Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2017</b> , 21, 401-414   | 6.4  | 24        |
| 62 | Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 195-203 | 7.5  | 24        |
| 61 | Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 700-711   | 3.5  | 21        |

|    |   |      |    |
|----|---|------|----|
| 60 | Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 237-246  | 7.5  | 20 |
| 59 | Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6  | 18 |
| 58 | Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127908   | 3.7  | 18 |
| 57 | New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 614-22   | 14.4 | 18 |
| 56 | Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. <i>Future Oncology</i> , <b>2015</b> , 11, 1809-28  | 3.6  | 16 |
| 55 | Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , <b>2017</b> , 8, 7328-7335  | 3.3  | 16 |
| 54 | Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 1367-9   | 3.5  | 16 |
| 53 | Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , <b>2018</b> , 10, 65-77   | 3.2  | 14 |
| 52 | Bladder cancer: molecular determinants of personalized therapy. <i>Current Drug Targets</i> , <b>2015</b> , 16, 115-243   |      | 14 |
| 51 | The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , <b>2015</b> , 10, 325-36   | 5    | 13 |
| 50 | Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , <b>2016</b> , 17, 150-5  | 3.5  | 13 |
| 49 | Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , <b>2018</b> , 13, 649-655   | 5    | 13 |
| 48 | Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1283-1289   | 3.8  | 12 |
| 47 | The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 161-175   | 3.5  | 12 |
| 46 | The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , <b>2018</b> , 24, 447-456 | 2.6  | 12 |
| 45 | Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , <b>2016</b> , 11, 569-577  | 5    | 12 |
| 44 | Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e1069-e1071   | 3.3  | 12 |
| 43 | Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , <b>2020</b> , 15, 495-501  | 5    | 12 |

|    |   |      |    |
|----|---|------|----|
| 42 | Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , <b>2015</b> , 11, 107-19   | 3.6  | 11 |
| 41 | Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 112-117  | 14.4 | 11 |
| 40 | The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , <b>2017</b> , 9, 579-587   | 3.8  | 10 |
| 39 | Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , <b>2019</b> , 46, 65-72        | 5.5  | 10 |
| 38 | PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , <b>2019</b> , 42, 269-273  | 5    | 10 |
| 37 | Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, 39-43                             | 1.9  | 7  |
| 36 | Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 296  | 8.5  | 7  |
| 35 | Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases. <i>International Journal of Biological Markers</i> , <b>2017</b> , 32, e243-e247  | 2.8  | 7  |
| 34 | Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 692-699   | 3.5  | 7  |
| 33 | Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , <b>2016</b> , 17, 757-70  | 3    | 6  |
| 32 | The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 681-96   | 3.5  | 6  |
| 31 | Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 139, 83-86 | 7    | 5  |
| 30 | Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: Game Over?. <i>Targeted Oncology</i> , <b>2016</b> , 11, 431-46  | 5    | 5  |
| 29 | Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 2559-2564  | 3.6  | 5  |
| 28 | Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , <b>2015</b> , 11, 1381-8  | 3.6  | 5  |
| 27 | Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <i>Cancers</i> , <b>2018</b> , 11,   | 6.6  | 5  |
| 26 | Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 1037-48   | 3.5  | 4  |
| 25 | Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 195-205   | 3.8  | 4  |

|    |   |      |   |
|----|---|------|---|
| 24 | De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 482-484   | 3.3  | 4 |
| 23 | Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 526.e13-526.e18 | 2.8  | 4 |
| 22 | Adenocarcinoma of the paraurethral glands: a case report. <i>Histology and Histopathology</i> , <b>2014</b> , 29, 1295-303  | 3.0  | 4 |
| 21 | Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 67, 29-33   | 14.4 | 3 |
| 20 | Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?. <i>European Urology</i> , <b>2016</b> , 69, 969-70  | 10.2 | 3 |
| 19 | Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. <i>American Journal of Cancer Research</i> , <b>2014</b> , 4, 907-15                             | 4.4  | 3 |
| 18 | Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , <b>2017</b> , 18, 723-726  | 3.5  | 3 |
| 17 | Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. <i>Journal of Onco-Nephrology</i> , <b>2017</b> , 1, 132-142  | 0.2  | 2 |
| 16 | The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2016</b> , 1, 369-377   | 1.6  | 2 |
| 15 | Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. <i>Future Science OA</i> , <b>2015</b> , 1, FSO29   | 2.7  | 2 |
| 14 | Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. <i>Pathology</i> , <b>2014</b> , 46, 523-6   | 1.6  | 2 |
| 13 | Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 435-435  | 2.2  | 2 |
| 12 | Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e124  | 21.7 | 1 |
| 11 | Kidney cancer and 2014: is innovation really over?. <i>Future Oncology</i> , <b>2015</b> , 11, 1437-49  | 3.6  | 1 |
| 10 | Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1  | 1 |
| 9  | Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 254-63   | 7    | 1 |
| 8  | The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 654-660   | 6.2  | 1 |
| 7  | Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 105, 102379  | 14.4 | 1 |

|   |   |     |   |
|---|---|-----|---|
| 6 | Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 469-73  | 2.4 | o |
| 5 | 2015 and human cancer: back to overall survival. <i>Future Oncology</i> , <b>2016</b> , 12, 1751-4  | 3.6 |   |
| 4 | Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 553-553   | 2.2 |   |
| 3 | How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16053-e16053 | 2.2 |   |
| 2 | Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 480-480  | 2.2 |   |
| 1 | 2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 1203-1206  | 3.5 |   |